Futura Medical’s FY25 results are a classic case of strong early promise running into cold commercial reality. Eroxon is now launched in 27 countries, patents are landing in key markets and the pipeline has moved forward, but the headline numbers are rough and cash is tight.
The big takeaway is simple: Eroxon has not sold as well as management hoped, repeat purchases have been weaker than expected, and Futura is now trying to reset the story with a new strategy, a tweaked commercial model and two pipeline projects – Eroxon Intense and WSD4000.
Futura Medical FY25 results: revenue collapse, losses return and balance sheet pressure
The top-line deterioration is stark. Revenue fell to £1.7 million from £13.9 million in FY24, while the group swung from an operating profit of £1.2 million to an operating loss of £9.1 million.
Some of that drop was always going to happen because FY24 included non-recurring milestone payments and initial stocking orders. Even so, this is still a nasty reset, and it tells you commercial traction has been much weaker than hoped.
| Key FY25 numbers | FY25 | FY24 |
|---|---|---|
| Revenue | £1.7 million | £13.9 million |
| Operating profit/(loss) | (£9.1 million) | £1.2 million |
| Adjusted operating profit/(loss) | (£8.6 million) | £3.3 million |
| Underlying operating profit/(loss) | (£4.5 million) | £3.3 million |
| Cash at year end | £3.4 million | £6.6 million |
| Basic EPS | (2.78 pence) | 0.43 pence |
There were also £4.05 million of exceptional items. These included a £3.22 million impairment of plant and equipment, which is accounting-speak for writing down assets because expected demand no longer supports their value, plus a £0.49 million inventory write-down and a £0.34 million final contractual payment tied to that impaired asset.
That matters because it shows management has had to admit some previous investment assumptions were too optimistic. It is better to clear the decks than pretend otherwise, but it is still a painful sign that the original launch plan has not worked.
Why Eroxon sales disappointed despite 27 country launches
Futura’s real problem is not distribution. Eroxon is now available in 27 countries, up from 18 at the end of 2024. The problem is what happens after launch – consumer uptake and repeat buying have been too slow.
The company says this has happened across the UK, EU, US, Middle East and Latin America. That broad weakness makes it harder to blame one partner, one market or one campaign. It points to a more fundamental issue around positioning and user experience.
Eroxon commercial problems management says it has now identified
- Customers may have compared Eroxon too directly with PDE5 inhibitors – the common oral erectile dysfunction drugs – and expected the same sort of result.
- Some consumers may not fully understand how and when to use the product correctly.
- Because it is over the counter, there is no healthcare professional guiding the right user to the right product.
- Targeting appears to have been too broad, including older men with severe ED who may be less likely to respond.
That is actually one of the most useful sections in the whole RNS. It shows the company now believes Eroxon’s issue is not that there is no market, but that the product has been marketed too loosely and explained too poorly.
My read is that this is both good news and bad news. Good news, because those are fixable commercial problems. Bad news, because consumer healthcare products live or die by repeat purchase, and weak repeat rates are a serious red flag.
Cash runway, Haleon patent milestone and the going concern warning
This is where investors need to stay sharp. Futura had £2.35 million of cash at the end of March 2026. The company says that, excluding the US patent milestone from Haleon, current cash resources are expected to provide runway only into June 2026.
With the US patent milestone, the runway is expected to extend into December 2026. That milestone is worth US$2.5 million, and Futura says it believes the conditions have been satisfied following the grant of a new US continuation patent on 17 March 2026.
However, the money has not yet been received. The board says it is in constructive discussions with Haleon, but until cash lands in the bank, it remains a risk.
The company is also explicit that there are material uncertainties around going concern. That does not mean collapse is imminent, but it does mean funding is a live issue now, not a theoretical one for next year.
There is another point here that should not be glossed over: dilution. Futura raised £2.75 million gross in December 2025, and total shares in issue rose to 581,327,755 from 303,703,568 a year earlier. That is a hefty increase, so any future fundraise could be painful for existing shareholders if it is done at a low price.
Futura Medical refined strategy: from hands-off licensing to hybrid commercial model
The strategic review has led to a meaningful shift. Futura says it is moving away from a model centred on R&D and full out-licensing to a hybrid R&D and commercial model.
In plain English, the old approach was more like “launch it with a partner and step back”. The new approach is “stay closer to the market, influence execution, share learnings across regions and try to keep more of the economics”.
On paper, that makes sense. If early launches have taught management that positioning, education and targeting matter hugely, then being more involved should help. The challenge is that a more active model can also require more people, more working capital and better execution. That is harder to do when cash is already tight.
Eroxon Intense and WSD4000 pipeline progress could still create value
This is the bit that keeps the investment case alive. Eroxon Intense, a reformulated version designed to give a faster and stronger sensorial effect, produced encouraging Home User Test results.
In a Home User Test of 223 men under 60 with mostly mild to moderate ED, subjects were satisfied with erection hardness in 70% of encounters using Eroxon and 71% using Eroxon Intense. Erections lasted long enough for intercourse in 84% and 85% of encounters respectively, and Eroxon Intense showed statistically significant stronger early sensorial effects.
That backs management’s plan to target younger men with mild to moderate ED more precisely. EU launch clearance is expected in June 2026, US FDA clearance in July 2026, and first market launches are expected in early 2027.
WSD4000, the female sexual health platform, is arguably even more interesting strategically. The company says there is currently no known regulatory approved OTC topical treatment available in major markets for female sexual dysfunction, so if this works, it could open up a much less crowded opportunity.
An Early Feasibility Study in 12 women showed what the company calls clear and positive trends. That is encouraging, but investors should keep perspective – this is still very early-stage and further work, including Home User Test results expected in June 2026 and a Phase 3 trial, remains subject to funding.
What Futura Medical shareholders should watch next
For me, this RNS is more reset than recovery. There are genuine positives – patents in the US and China until 2040, a more realistic assessment of Eroxon’s launch issues, promising pipeline signals and a clearer commercial strategy. But the negatives are impossible to ignore: revenue has fallen off a cliff, losses are back, assets have been impaired and the cash runway is short without Haleon’s milestone payment.
In the near term, three things matter most:
- whether the US$2.5 million Haleon patent milestone is received and when
- whether Futura can secure additional funding without excessive dilution
- whether Eroxon repositioning starts to improve repeat purchase trends
If those three go the right way, the shares could start to rebuild on a more credible footing. If they do not, this becomes a funding story first and a growth story second.
That is the honest reading of this announcement. Futura still has assets worth talking about, but it now has to prove it can turn scientific promise and market access into actual consumer demand before the cash clock runs down.
